Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mast cell degranulation mediator release is a critical immunological event involving the regulated secretion of diverse pre-stored molecules from cytoplasmic granules following cellular activation. These events drive both protective immunity against pathogens/allergens and contribute pathologically to allergic diseases when dysregulated.
Varies depending on the drug. Antihistamines block histamine receptors. Corticosteroids reduce inflammation. Epinephrine reverses anaphylaxis. Mast cell stabilizers prevent degranulation. Omalizumab prevents IgE binding to mast cells.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mast Cell Degranulation Mediator Release (N/A).